SAFETY DATA SHEET

Tafluprost Formulation

Version: 1.10  Revision Date: 09.04.2021  SDS Number: 558031-00011  Date of last issue: 10.10.2020  Date of first issue: 15.03.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
    Trade name: Tafluprost Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
    Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
    Company: MSD
    117 16th Road
    1685 Halfway house, Midrand, South Africa
    Telephone: +27 11 655 3000
    E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
    +1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
    Classification (REGULATION (EC) No 1272/2008)
    Not a hazardous substance or mixture.

2.2 Label elements
    Labelling (REGULATION (EC) No 1272/2008)
    Not a hazardous substance or mixture.

2.3 Other hazards
    This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tafluprost</td>
<td>209860-87-7</td>
<td></td>
<td></td>
<td></td>
<td>Acute Tox. 4; H302</td>
<td>&gt;= 0.0002 - &lt;</td>
</tr>
</tbody>
</table>
SECTION 4: First aid measures

4.1 Description of first aid measures

Protection of first-aiders: No special precautions are necessary for first aid responders.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed
None known.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.
5.3 Advice for firefighters

Special protective equipment for firefighters
Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up
Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures
See Engineering measures under EXPOSURE
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.
Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerine</td>
<td>56-81-5</td>
<td>TWA OEL-RL (Mist)</td>
<td>10 mg/m³</td>
<td>ZA OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tafluprost</td>
<td>209860-87-7</td>
<td>TWA</td>
<td>0.002 µg/m³ (OEB 5)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>0.02 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerine</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>56 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>229 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>33 mg/m³</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Tafluprost Formulation

Version 1.10  Revision Date: 09.04.2021  SDS Number: 558031-00011  Date of last issue: 10.10.2020  Date of first issue: 15.03.2016

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerine</td>
<td>Fresh water</td>
<td>0.885 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.0885 mg/l</td>
</tr>
<tr>
<td></td>
<td>Intermittent use/release</td>
<td>8.85 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>1000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>3.3 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>0.33 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>0.141 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves

Remarks: Consider double gloving.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Organic vapour type (A)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance: Aqueous solution
Colour: clear
Odour: No data available
Odour Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : No data available
Evaporation rate : No data available
Flammability (solid, gas) : Not applicable
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
Relative vapour density : No data available
Relative density : No data available
Density : No data available
Solubility (ies)
  Water solubility : No data available
  Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information
Flammability (liquids) : No data available
Molecular weight : No data available
Particle size : No data available
SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:
Tafluprost:
Acute oral toxicity: LD50 (Rat): 665 mg/kg
LD50 (Rat): > 100 mg/kg
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration): (Dog): 3 mg/kg
Target Organs: Cardio-vascular system

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Tafluprost:
### Tafluprost Formulation

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No eye irritation</td>
</tr>
</tbody>
</table>

#### Respiratory or skin sensitisation

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

### Components:

#### Tafluprost:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Maximisation Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure routes</td>
<td>Dermal</td>
</tr>
<tr>
<td>Species</td>
<td>Guinea pig</td>
</tr>
<tr>
<td>Result</td>
<td>Not a skin sensitizer.</td>
</tr>
</tbody>
</table>

#### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Tafluprost:

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotoxicity in vivo</th>
<th>Test Type: Chromosome aberration test in vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotoxicity in vivo</th>
<th>Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Species: Mouse</td>
</tr>
<tr>
<td></td>
<td>Application Route: Intraperitoneal injection</td>
</tr>
<tr>
<td></td>
<td>Result: negative</td>
</tr>
</tbody>
</table>

#### Carcinogenicity

Not classified based on available information.

### Components:

#### Tafluprost:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>24 Months</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>18 Months</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>
Reproductive toxicity
Not classified based on available information.

**Components:**

**Tafluprost:**

Effects on fertility

- **Test Type:** Fertility/early embryonic development
- **Species:** Rat
- **Application Route:** Intravenous injection
- **Fertility:** NOAEL: 100 µg/kg
- **Result:** No effects on fertility

Effects on foetal development

- **Test Type:** Embryo-foetal development
- **Species:** Rat
- **Application Route:** Intravenous injection
- **Developmental Toxicity:** LOAEL: 10 µg/kg
- **Result:** Malformations were observed., Reduced foetal weight

- **Test Type:** Embryo-foetal development
- **Species:** Rat
- **Application Route:** Intravenous injection
- **Developmental Toxicity:** NOAEL: 3 µg/kg

- **Test Type:** Embryo-foetal development
- **Species:** Rabbit
- **Application Route:** Intravenous injection
- **Developmental Toxicity:** LOAEL: 0.03 µg/kg
- **Result:** Malformations were observed.

- **Test Type:** Embryo-foetal development
- **Species:** Rabbit
- **Application Route:** Intravenous injection
- **Developmental Toxicity:** NOAEL: 0.01 µg/kg

- **Test Type:** Embryo-foetal development
- **Species:** Rat
- **Application Route:** Intravenous injection
- **Developmental Toxicity:** LOAEL: 1 µg/kg

- **Test Type:** Embryo-foetal development
- **Species:** Rat
- **Application Route:** Intravenous injection
- **Developmental Toxicity:** NOAEL: 0.3 µg/kg

Reproductive toxicity - Assessment

- Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**Components:**

**Tafluprost:**

**Target Organs**

- Lungs, Cardio-vascular system

**Assessment**

- Causes damage to organs.
STOT - repeated exposure
Not classified based on available information.

Components:
Tafluprost:
Target Organs: Lungs, Cardio-vascular system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity
Components:
Tafluprost:
Species: Rat
LOAEL: 0.01 mg/kg
Application Route: Intravenous
Exposure time: 6 Months
Target Organs: Cardio-vascular system, Blood, Bone marrow, Kidney, Liver, spleen

Species: Dog
NOAEL: 0.0001 mg/kg
LOAEL: 0.001 mg/kg
Application Route: Intravenous
Exposure time: 39 Weeks
Target Organs: Cardio-vascular system, Eye
Symptoms: Dilatation of the pupil

Aspiration toxicity
Not classified based on available information.

Experience with human exposure
Components:
Tafluprost:
Eye contact: Symptoms: dryness of the eyes, Blurred vision

SECTION 12: Ecological information

12.1 Toxicity
No data available

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
Components:
Tafluprost:
12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment

Product:
Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:
Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable
SAFETY DATA SHEET

Tafluprost Formulation

Version 1.10  Revision Date: 09.04.2021  SDS Number: 558031-00011  Date of last issue: 10.10.2020
Date of first issue: 15.03.2016

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302: Harmful if swallowed.
H319: Causes serious eye irritation.
H360D: May damage the unborn child.
H370: Causes damage to organs if swallowed.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.
H413: May cause long lasting harmful effects to aquatic life.

Full text of other abbreviations

Acute Tox.: Acute toxicity
Aquatic Chronic: Long-term (chronic) aquatic hazard
Eye Irrit.: Eye irritation
Repr.: Reproductive toxicity
STOT RE: Specific target organ toxicity - repeated exposure
STOT SE: Specific target organ toxicity - single exposure
ZA OEL: South Africa. Hazardous Chemical Substances Regulations, Occupational Exposure Limits
ZA OEL / TWA OEL-RL: Long term occupational exposure limits - recommended limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -
SAFETY DATA SHEET

Tafluprost Formulation

Version 1.10
Revision Date: 09.04.2021
SDS Number: 558031-00011
Date of last issue: 10.10.2020
Date of first issue: 15.03.2016

Further information

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

ZA / EN